A combination of urinary biomarker panel and PancRISK score for earlier detection of pancreatic cancer: A case–control study

Published on Dec 10, 2020in PLOS Medicine10.5
· DOI :10.1371/JOURNAL.PMED.1003489
Silvana Debernardi17
Estimated H-index: 17
(QMUL: Queen Mary University of London),
Harrison O’Brien1
Estimated H-index: 1
(QMUL: Queen Mary University of London)
+ 13 AuthorsTatjana Crnogorac-Jurcevic34
Estimated H-index: 34
(QMUL: Queen Mary University of London)
Publisher Copyright: © 2020 Debernardi et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
#1Stephen P. Pereira (UCL: University College London)H-Index: 61
#2Lucy Oldfield (University of Liverpool)H-Index: 4
Last. Eithne Costello (University of Liverpool)H-Index: 51
view all 14 authors...
Pancreatic ductal adenocarcinoma is most frequently detected at an advanced stage. Such late detection restricts treatment options and contributes to a dismal 5-year survival rate of 3-15%. Pancreatic ductal adenocarcinoma is relatively uncommon and screening of the asymptomatic adult population is not feasible or recommended with current modalities. However, screening of individuals in high-risk groups is recommended. Here, we review groups at high risk for pancreatic ductal adenocarcinoma, inc...
42 CitationsSource
#1Kathrin Schilling (University of Oxford)H-Index: 3
#1Kathrin Schilling (LDEO: Lamont–Doherty Earth Observatory)H-Index: 3
Last. Tatjana Crnogorac-Jurcevic (QMUL: Queen Mary University of London)H-Index: 34
view all 8 authors...
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest types of cancer. Its high mortality rate is attributed largely to the difficulty of early diagnosis. Analysis of urine is an excellent non-invasive approach to trace changes in biochemical reactions due to cancer development. Here we show remarkable differences in concentration of several essential metals: significantly lower levels of urinary calcium and magnesium and increased levels of copper and zinc in PDAC when compared to hea...
13 CitationsSource
#1Oleg Blyuss (University of Hertfordshire)H-Index: 15
#2Alexey Zaikin (UCL: University College London)H-Index: 26
Last. Tatjana Crnogorac-Jurcevic (QMUL: Queen Mary University of London)H-Index: 34
view all 8 authors...
An accurate and simple risk prediction model that would facilitate earlier detection of pancreatic adenocarcinoma (PDAC) is not available at present. In this study, we compare different algorithms of risk prediction in order to select the best one for constructing a biomarker-based risk score, PancRISK. Three hundred and seventy-nine patients with available measurements of three urine biomarkers, (LYVE1, REG1B and TFF1) using retrospectively collected samples, as well as creatinine and age, were...
11 CitationsSource
#2Mazhar Soufi (Indiana University Health)H-Index: 2
Last. C. Max SchmidtH-Index: 4
view all 7 authors...
Abstract Background Intraductal papillary mucinous neoplasms (IPMN) are precursors of pancreatic cancer. Potential biomarkers of IPMN progression have not been identified in urine. A few urinary biomarkers were reported to be predictive of pancreatic ductal adenocarcinoma (PDAC). Here, we seek to assess their ability to detect high-risk IPMN. Methods Urine was collected from patients undergoing pancreatic resection and healthy controls. TIMP-1(Tissue Inhibitor of Metalloproteinase-1), LYVE-1(Lym...
4 CitationsSource
#1Melina Arnold (IARC: International Agency for Research on Cancer)H-Index: 24
#2Mark J. Rutherford (IARC: International Agency for Research on Cancer)H-Index: 17
Last. Freddie Bray (IARC: International Agency for Research on Cancer)H-Index: 119
view all 38 authors...
Summary Background Population-based cancer survival estimates provide valuable insights into the effectiveness of cancer services and can reflect the prospects of cure. As part of the second phase of the International Cancer Benchmarking Partnership (ICBP), the Cancer Survival in High-Income Countries (SURVMARK-2) project aims to provide a comprehensive overview of cancer survival across seven high-income countries and a comparative assessment of corresponding incidence and mortality trends. Met...
174 CitationsSource
#1Chia-Ning Shen (AS: Academia Sinica)H-Index: 27
#2King Siang Goh (AS: Academia Sinica)H-Index: 6
Last. Shiue-Cheng Tang (NTHU: National Tsing Hua University)H-Index: 17
view all 15 authors...
Abstract Background The lymphatic system is involved in metastasis in pancreatic cancer progression. In cancer staging, lymphatic spread has been used to assess the invasiveness of tumor cells. However, from the endothelium's perspective, the analysis downplays the peri-lesional activities of lymphatic vessels. This unintended bias is largely due to the lack of 3-dimensional (3-D) tissue information to depict the lesion microstructure and vasculature in a global and integrated fashion. Methods W...
3 CitationsSource
#1Kassaporn Duangkumpha (KKU: Khon Kaen University)H-Index: 4
#2Thomas Stoll (QIMR: QIMR Berghofer Medical Research Institute)H-Index: 10
Last. Watcharin Loilome (KKU: Khon Kaen University)H-Index: 29
view all 15 authors...
Cholangiocarcinoma (CCA) is a primary malignant tumor of the epithelial lining of biliary track associated with endemic Opisthorchis viverrini (Ov) infection in northeastern Thailand. Ov-associated periductal fibrosis (PDF) is the precancerous lesion for CCA, and can be detected by ultrasonography (US) to facilitate early detection. However, US cannot be used to distinguish PDF from cancer. Therefore, the objective of this study was to discover and qualify potential urine biomarkers for CCA dete...
10 CitationsSource
#1Sarah S Dinges (Charité)H-Index: 3
#2Annika Hohm (Harvard University)H-Index: 3
Last. Leo L. Cheng (Harvard University)H-Index: 24
view all 7 authors...
Urinary tests have been used as noninvasive, cost-effective tools for screening, diagnosis and monitoring of diseases since ancient times. As we progress through the 21st century, modern analytical platforms have enabled effective measurement of metabolites, with promising results for both a deeper understanding of cancer pathophysiology and, ultimately, clinical translation. The first study to measure metabolomic urinary cancer biomarkers using NMR and mass spectrometry (MS) was published in 20...
38 CitationsSource
#1Aatur D. Singhi (University of Pittsburgh)H-Index: 41
#2Eugene J. Koay (University of Texas MD Anderson Cancer Center)H-Index: 34
Last. Anirban Maitra (University of Texas MD Anderson Cancer Center)H-Index: 136
view all 4 authors...
Most patients with pancreatic ductal adenocarcinoma (PDAC) present with symptomatic, surgically unresectable disease. Although the goal of early detection of PDAC is laudable and likely to result in significant improvement in overall survival, the relatively low prevalence of PDAC renders general population screening infeasible. The challenges of early detection include identification of at-risk individuals in the general population who would benefit from longitudinal surveillance programs and a...
139 CitationsSource
#1Kazufumi Honda (Japan Agency for Medical Research and Development)H-Index: 12
#1Kazufumi Honda (Japan Agency for Medical Research and Development)H-Index: 40
Last. Rudolf Kaaks (DKFZ: German Cancer Research Center)H-Index: 12
view all 42 authors...
Recently, we identified unique processing patterns of apolipoprotein A2 (ApoA2) in patients with pancreatic cancer. Our study provides a first prospective evaluation of an ApoA2 isoform (“ApoA2-ATQ/AT”), alone and in combination with carbohydrate antigen 19–9 (CA19-9), as an early detection biomarker for pancreatic cancer. We performed ELISA measurements of CA19-9 and ApoA2-ATQ/AT in 156 patients with pancreatic cancer and 217 matched controls within the European EPIC cohort, using plasma sample...
18 CitationsSource
Cited By3
#1Guru TrikudanathanH-Index: 20
#2Emil Lou (UMN: University of Minnesota)H-Index: 27
Last. Shounak Majumder (Mayo Clinic)H-Index: 13
view all 4 authors...
PURPOSE OF REVIEW Pancreatic ductal adenocarcinoma (PDAC) is third leading cause of cancer death in the United States, a lethal disease with no screening strategy. Although diagnosis at an early stage is associated with improved survival, clinical detection of PDAC is typically at an advanced symptomatic stage when best in class therapies have limited impact on survival. RECENT FINDINGS In recent years this status quo has been challenged by the identification of novel risk factors, molecular mar...
#1Jie Cai (Peking Union Medical College Hospital)
#2Hongda Chen (Peking Union Medical College)H-Index: 16
Last. Yupei Zhao (Peking Union Medical College Hospital)H-Index: 34
view all 9 authors...
Abstract null null Pancreatic cancer is a malignancy with poor prognosis and high mortality. The recent increase in pancreatic cancer incidence and mortality has resulted in an increased number of studies on its epidemiology. This comprehensive and systematic literature review summarizes the advances in the epidemiology of pancreatic cancer, including its epidemiological trends, risk factors, risk prediction models, screening modalities, and prognosis. The risk factors for pancreatic cancers can...
#1Greta Brezgyte (QMUL: Queen Mary University of London)
#2Vinay Shah (QMUL: Queen Mary University of London)
Last. Tatjana Crnogorac-Jurcevic (QMUL: Queen Mary University of London)H-Index: 34
view all 4 authors...
Pancreatic ductal adenocarcinoma (PDAC) carries a deadly diagnosis, due in large part to delayed presentation when the disease is already at an advanced stage. CA19-9 is currently the most commonly utilized biomarker for PDAC; however, it lacks the necessary accuracy to detect precursor lesions or stage I PDAC. Novel biomarkers that could detect this malignancy with improved sensitivity (SN) and specificity (SP) would likely result in more curative resections and more effective therapeutic inter...
1 CitationsSource
Last. Jaime FeliuH-Index: 28
view all 3 authors...
Pancreatic ductal adenocarcinoma (PDAC) exhibits the poorest prognosis of all solid tumors, with a 5-year survival of less than 10%. To improve the prognosis, it is necessary to advance in the development of tools that help us in the early diagnosis, treatment selection, disease monitoring, evaluation of the response and prognosis. Liquid biopsy (LB), in its different modalities, represents a particularly interesting tool for these purposes, since it is a minimally invasive and risk-free procedu...
1 CitationsSource